Literature DB >> 21959789

Predicting response to psychopharmacological treatment: survey of recent results.

H Stassen1, I-G Anghelescu, J Angst, H Böker, K Lötscher, D Rujescu, A Szegedi, C Scharfetter.   

Abstract

INTRODUCTION: Treatment with antidepressants and antipsychotics, though effective, is unspecific as agents that differ greatly in their biochemical and pharmacological actions have virtually the same efficacy. Half of the patients with initial improvement show incomplete response, while a large proportion of patients exhibit a refractory clinical picture which is resistant to all treatment modalities.
METHODS: Our analyses were based on a reference study of 2,848 depressive inpatients under monotherapeutic treatment with 7 different antidepressants or placebo, along with a naturalistic study of depressive and schizophrenic patients (296 inpatients, 363 outpatients) under today's "standard" polypharmaceutic treatment regimens.
RESULTS: The empirical data suggested the following predictors of response: (1) severity at baseline, (2) early onset of improvement, (3) unwanted side-effects, and (4) medical comorbidity. A combination of these predictors with Therapeutic Drug Monitoring (TDM) methods has direct clinical relevance. DISCUSSION: Evidence-based approaches to personalized treatment help improving the unsatisfactory situation patients and clinicians are faced with, given today's incomplete treatments and the fact that the mechanisms by which antidepressants and antipsychotics ultimately exert their therapeutic effects are only marginally understood. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959789     DOI: 10.1055/s-0031-1286290

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

1.  [Predictive factors of depression and its therapy].

Authors:  H Himmerich; E Kohls; U Hegerl; C Rummel-Kluge
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

2.  The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Authors:  J M Biernacka; K Sangkuhl; G Jenkins; R M Whaley; P Barman; A Batzler; R B Altman; V Arolt; J Brockmöller; C H Chen; K Domschke; D K Hall-Flavin; C J Hong; A Illi; Y Ji; O Kampman; T Kinoshita; E Leinonen; Y J Liou; T Mushiroda; S Nonen; M K Skime; L Wang; B T Baune; M Kato; Y L Liu; V Praphanphoj; J C Stingl; S J Tsai; M Kubo; T E Klein; R Weinshilboum
Journal:  Transl Psychiatry       Date:  2015-04-21       Impact factor: 6.222

3.  Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.

Authors:  Roger S McIntyre; Philip Gorwood; Michael E Thase; Charlie Liss; Dhaval Desai; Ji Chen; Michael Bauer
Journal:  J Clin Psychopharmacol       Date:  2015-12       Impact factor: 3.153

4.  Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy.

Authors:  H H Stassen; S Bachmann; R Bridler; K Cattapan; D Herzig; A Schneeberger; E Seifritz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-07-21       Impact factor: 5.270

5.  Monitoring the effects of therapeutic interventions in depression through self-assessments.

Authors:  Ines Moragrega; René Bridler; Christine Mohr; Michela Possenti; Deborah Rochat; Judit Sanchez Parramon; Hans H Stassen
Journal:  Res Psychother       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.